Table 1 Baseline clinical and laboratory factors of the aspirin group and cilostazol group
|  | Aspirin (n = 34) | Cilostazol (n = 32) | P |
|---|---|---|---|
Age | 59.5 ± 11.7 | 57.4 ± 12.7 | 0.494 |
Male sex | 20 (58.8%) | 23 (71.9%) | 0.266 |
TOAST classification | Â | Â | 0.233 |
 Atherosclerosis | 1 (2.9%) | 3 (9.4%) |  |
 Small artery disease | 28 (82.4%) | 28 (87.5%) |  |
 Unknown | 3 (8.8%) | 0 (0.0%) |  |
 Transient ischemic attack | 2 (5.9%) | 1 (3.1%) |  |
HTN | 28 (82.4%) | 22 (68.8%) | 0.197 |
DM | 10 (29.4%) | 5 (15.6%) | 0.182 |
Cardiac problems | 3 (8.8%) | 2 (6.3%) | 0.693 |
Hyperlipidemia | 13 (38.2%) | 14 (43.8%) | 0.649 |
Metabolic syndrome | 20 (58.8%) | 14 (43.8%) | 0.324 |
BMI | 24.9 ± 3.1 | 24.6 ± 3.0 | 0.994 |
Smoking | 16 (47.1%) | 13 (40.6%) | 0.599 |
Previous statin use | 1 (2.9%) | 2 (6.3%) | 0.519 |
Laboratory data | |||
 Hemoglobin (mg/dL) | 14.0 ± 2.0 | 14.2 ± 1.4 | 0.638 |
 Glucose (mg/dL) | 147.9 ± 62.9 | 130.2 ± 37.8 | 0.173 |
 CRP (mg/dL) | 0.2 ± 0.3 | 0.2 ± 0.3 | 0.692 |
 Fibrinogen (mg/dL) | 319.4 ± 70.4 | 327.1 ± 78.7 | 0.678 |
 Homocysteine (mg/dL) | 12.0 ± 4.5 | 12.3 ± 6.4 | 0.84 |
 L-arginine (mmol/L) | 98.3 ± 42.6 | 95.0 ± 25.1 | 0.706 |
Lipid | |||
 Total cholesterol (mg/dL) | 192.6 ± 35.6 | 193.6 ± 38.6 | 0.913 |
 Triglyceride (mg/dL) | 157.7 ± 102.4 | 135.0 ± 67.4 | 0.296 |
 HDL (mg/dL) | 45.0 ± 12.8 | 44.7 ± 9.7 | 0.921 |
 LDL (mg/dL) | 118.5 ± 29.7 | 121.8 ± 33.1 | 0.669 |